ClinicalTrials.gg
Not yet recruitingNCT07262385Updated Dec 3, 2025

Calmer Brains in Very Preterm Infants

An interventional study of Calmer in Premature Infant, sponsored by University of British Columbia. Not yet recruiting at 1 site in Canada. Open to participants aged 26 Weeks to 30 Weeks. Per ClinicalTrials.gov, last updated 2025-12-03.

Sponsored by University of British Columbia · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
26 Weeks to 30 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 139 studies in Premature Birth with a site in Canada — 26 open to participants now, 34 under way, 2 of them phase 3. Premature Birth · Canada.

Planned enrollment
90th of 106
20 · median 80
Started
2025
with 6 others
No phase
65 of 139
9 open now
Primary completion
2027-04
later than 22 of 33 live
Registered
132nd of 139
by date
Lead sponsor
8 of 139
University of British Columbia

Among the 139 studies in Premature Birth with a site in Canada, this one is the 90th largest by planned enrollment of the 106 interventional ones that give a count, is one of 7 that started in 2025, is one of 65 with no phase, reaches primary completion later than 22 of the 33 other live ones, and was the 132nd registered.

Premature Birth

2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

Browse Premature Birth studies →

Open to participants now

26 of the 139 studies in Premature Birth with a site in Canada are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.

This study: 26 Weeks to 30 Weeks · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Premature Birth with a site in Canada, or all of them as a file.
02

Study summary

Very preterm infants in the neonatal intensive care unit (NICU) need lifesaving medical procedures which can be stressful and affect brain development. Calmer was invented to mimic key parts of parental holding (touch, heartbeat sounds and breathing motion) to help reduce stress if parents cannot be there to hold their infant. Using specialized brain scans done at full term, we will gather initial information in 22 infants born 3-4 months early to compare brain development in infants who receive Calmer at least 3 hours each day (+ regular NICU care) over 2-3 weeks with infants who have regular NICU care.

Read the detailed description

Very preterm infants (\< 32 weeks gestational age [GA]) experience developmentally unexpected, repeated stress as part of lifesaving care in the NICU during a period of considerable brain maturation and growth. Exposure to early-life stress alters brain maturation resulting in long-term changes in neurodevelopment. Parental skin-to-skin care (SSC) can mitigate stress; however, parents are not always available. Calmer, a patented, therapeutic medical device, was invented to simulate aspects of SSC (skin-like surface, breathing motion, heartbeat sounds) with rates of the latter two individualized for each infant. In a randomized trial, Calmer has been shown to stabilize brain blood flow during a single, routine blood test. Most recently, we found that very preterm infants who received Calmer treatment for 3 continuous weeks had 25% greater head growth compared to controls. However, we do not know if/how Calmer treatment affects brain development in very preterm infants.

Objectives: We will gather pilot data for a larger trial to examine differences in brain structural and functional development in very preterm infants who receive Calmer treatment for 2-3 consecutive weeks compared to controls.

Methods: 22 infants born 26-30 weeks GA admitted to BC Women's Hospital NICU will be randomized to either control (n=11) or treatment groups (n=11; Calmer for 2-3 continuous weeks, 3 hours/day minimum treatment). Infants from both groups will undergo feed and bundle MRI scans at term-equivalent age using high resolution volumetric, diffusion and resting-state functional MRI to explore group differences in whole-brain volumes and structural and functional connectivity. Images will be processed using existing quantitative neonatal imaging analysis pipelines in the Selvanathan and Weber labs at BC Children's Hospital Research Institute. Analyses will include: measures of trial feasibility and description of brain differences between groups.

Significance: Ultimately, Calmer may support healthy brain maturation optimizing the neurodevelopment of vulnerable infants in Canada and beyond.

03

Conditions studied

  • Premature Infant

Browse trials for

Keywords

  • Prematurity
  • Brain development
  • Stress
  • NICU
  • Pilot RCT
  • Feasibility
  • Calmer - therapeutic medical device
04

Who can participate

Ages eligible
26 Weeks to 30 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Very preterm infants admitted to the NICU at the BC Women's Hospital

Exclusion Criteria: Infants who have

  • Congenital anomalies;
  • Born small for GA (per medical admission history);
  • History of birthing parent substance use in pregnancy;
  • Ongoing infection at the time of enrollment;
  • Pre-existing cardiovascular instability defined by shock/hypotension/need for cardiovascular drugs;
  • Receiving paralytic drugs;
  • Major neurological injury (e.g. hypoxic ischemic encephalopathy, hemorrhage/stroke; VP shunt);
  • Beyond the 30th completed week GA (30 weeks + 6 days) at enrollment.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Calmer

    Infants in the Calmer group will have a Calmer\* placed and left in their incubators for a minimum of 2 and maximum of 3 weeks and will receive treatment for a minimum cumulative total of 3 hours/day (i.e. time can be discontinuous). Each day, after the infant's parent rests for 10 minutes, the research and/or bedside nurse will record the heart and respiratory rates for a 2-minute period (or taken by the caregiver themselves after training by research/NICU staff). The 1-minute average will be used to program Calmer for each infant that day to better simulate day-to-day changes in infant-parent contact. The values can be adjusted over the day as parents wish. \*Calmer, a patented, therapeutic bed that mimics key aspects of skin-to-skin care (SSC) to reduce stress in preterm infants. Calmer fits into NICU incubators and delivers 3 key SSC stimuli: touch, breathing motion, and heartbeat sounds (rates individualized to each infant based on their parents' HR/RR).

    Device: Calmer

  • No intervention
    Control

    Infants in the Control group will receive standard NICU care, including parent SSC.

Interventions

  • DeviceCalmer

    Calmer, a unique, patented, therapeutic bed that mimics key aspects of SSC that reduce stress in preterm infants. Calmer fits into NICU incubators and cribs, and delivers 3 key SSC stimuli: touch, breathing motion, and heartbeat sounds; the rates of the latter 2 stimuli are individualized to each infant based on their parents' breathing and heart rates. Calmer is designed to provide complementary care only when parents are not able to give SSC. It is not meant nor designed to replace human SSC, so will never be tested as such a replacement. Instead, Calmer was invented to enhance and optimize brain development in preterm infants by reducing stress during the NICU stay, when parents/caregivers are not available for SSC. Our ultimate goal is to enable use of Calmer from an infant's admission to discharge, only during those times when caregivers are not available.

06

What researchers measure

Primary outcomes

  1. Brain Volumes

    Anatomical analysis: Anatomical images (T2w) will be manually inspected for quality control. Images with very poor tissue contrast or motion artefacts will be rejected. T2w images will be bias-field corrected using ANTs N4ITK. The images will then be skull-stripped and segmented using the dHCP anatomical pipeline to calculate total and sub-regional brain volumes.

    Time frame: When each participant reaches 40 weeks post-conceptual age and return for their MRI scan

  2. Brain Functional Connectivity

    Resting state fMRI analysis: Fieldmaps will be generated using the dual-echo EPI and magnitude scan. The dHCP functional pipeline will be implemented to achieve distortion-correction and motion-correction, register the functional image to the corresponding T2w structural image, generate a transform matrix from functional space to the 40-week T2w template; and we will perform temporal high-pass filtering (150 s high-pass cutoff) and independent component analysis (ICA) denoising using ICA FIX. Scans with a mean FD \> 1 mm will be excluded. The dHCP functional pipeline will then be run on all subjects using the study-specific training file. Spatial smoothing of 5 mm will be applied using FSL's SUSAN and grand mean intensity normalization will be computed. Functional connectivity measures will be computed using the CONN toolbox.

    Time frame: When each participant reaches 40 weeks post-conceptual age

  3. Brain Fractional Anisotropy

    Diffusion tensor imaging analysis: The dHCP neonatal dMRI data processing pipeline will be used to pre-process the diffusion weighted images. Briefly, opposite phase b0 images are used to estimate the off-resonance field that is then used in the simultaneous correction of motion artefacts, susceptibility-induced and eddy current distortions. Data will then be super-resolved and, after pre-processing is complete, local diffusion and microstructural models are fitted in every voxel and averaged to calculate mean fractional anisotropy.

    Time frame: When participants reach term-equivalent age

Secondary outcomes

  1. Clinical weight measures

    Weight: infant weight in kilograms captured when enrolled in the study (i.e. baseline T1) and end of experimental phase (2-3 weeks later; T2) We will use the weight measure to determine changes between baseline and the end of treatment.

    Time frame: From the start of study treatment (or enrolment if Control group) to 2-3 weeks later, at the end of intervention exposure.

  2. Head growth measures

    Head circumference: infant head circumference in centimetres (occipito-frontal circumference) captured when enrolled in the study (i.e. baseline T1) and end of experimental phase (2-3 weeks later; T2). We will use the head circumference measures to determine changes between baseline and the end of treatment.

    Time frame: From the start of study treatment (or enrolment if Control group) to 2-3 weeks later, at the end of intervention exposure.

Other outcomes

  1. Trial feasibility

    Consent rate: overall average consent rate of infants/month

    Time frame: 2 years from the start of the study

  2. Trial feasibility

    Protocol delivery: % of on/off protocol infants

    Time frame: 2 years from the start of the study

  3. Trial feasibility

    Outcome measures: % of infants with complete primary outcome data

    Time frame: 2 years from the start of the study

  4. Trial feasibility

    Rate/nature of safety issues

    Time frame: 2 years from the start of the study

07

Study locations

1 site
  • BC Women's Hospital & Health Centre
    Vancouver, British Columbia V6H 3N1, Canada
    • Manon Ranger, PhD · Contactmanon.ranger@ubc.ca · 604-827-1382
    • Manon Ranger, PhD · Principal investigator
    • Liisa Holsti, PhD · Principal investigator
08

References and documents

Publications

  • Holsti L, MacLean K, Oberlander T, Synnes A, Brant R. Calmer: a robot for managing acute pain effectively in preterm infants in the neonatal intensive care unit. Pain Rep. 2019 Mar 14;4(2):e727. doi: 10.1097/PR9.0000000000000727. eCollection 2019 Mar-Apr. PubMed 31041426 ↗
  • Ranger M, Albert A, MacLean K, Holsti L. Cerebral hemodynamic response to a therapeutic bed for procedural pain management in preterm infants in the NICU: a randomized controlled trial. Pain Rep. 2021 Jan 12;6(1):e890. doi: 10.1097/PR9.0000000000000890. eCollection 2021 Jan-Feb. PubMed 33490850 ↗

Individual participant data

Plan to share: Yes — As part of this study, participants' de-identified research data may be shared in a public database when the research is published. Sharing this deidentified data helps make research more transparent and allows others to double-check the results. It also means that other researchers can use the data for different studies in the future, beyond the scope of this current study. The exact details have not been decided yet.

Supporting information: Study protocol, Clinical study report, Analytic code

Time frame: When the research findings are published.

Access criteria: We have not decided on these details.

Data sharing details ↗ · notcurrentlyavailable.ca

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Apr 2027, 16 months later.

Of 746 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 16 months is below that.

Counting every sponsor, half of 764 studies reached it within 24 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2025
First posted
Dec 3, 2025
StartEst.
Dec 1, 2025
Primary completionEst.
Apr 2027
CompletionEst.
Sep 2027
Last update
Dec 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07262385
Collaborators
BC Children's Hospital Research Institute
Responsible party
Manon Ranger (Assistant Professor, University of British Columbia) — Principal investigator
First posted
Dec 3, 2025
Start date
Dec 1, 2025 (estimated)
Primary completion
Apr 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Dec 3, 2025

Study contacts

Manon Ranger, PhD
Contact
manon.ranger@ubc.ca
604-827-1382
Manon Ranger, PhD
principal investigator · University of British Columbia
Liisa Holsti, PhD
principal investigator · University of British Columbia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion